Immunobrain Checkpoint

Organisation

People

Eti Yoles
Chief operating officer

Sources: reporter.nih.gov

Grants and prizes

National Institute on Aging
R01, First-in-Human (Phase 1) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of IBC-Ab002 in Persons with Early Alzheimer's Disease (AD), R01AG071810, US$1.3m, 2021–2024, 1 Sept 2023

Sources: reporter.nih.gov

Named in competing interests

Depression severity and sleep efficiency's associations with amyloid burden are additive but dependent on underlying genetic risk in late life depression
Consulting or advice, 9 Oct 2026

Sources: pubmed.ncbi.nlm.nih.gov